Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Lenvatinib (n = 478) | Sorafenib (n = 476) | HR, P-value | |
OS (M, 95% CI) | 13.6 (12.1-14.9) | 12.3 (10.4-13.9) | HR 0.92 (0.79-1.06) |
PFS (M, 95% CI) | 7.3 (5.6-7.5) | 3.6 (3.6-3.7) | HR 0.64 (0.55-0.75) P < 0.0001 |
TTP (M, 95% CI) | 7.4 (7.2-9.1) | 3.7 (3.6-3.9) | HR 0.60 (0.51-0.71) P < 0.0001 |
Objective response (independent review, mRECIST) | |||
CR | 10 (2%) | 4 (1%) | |
PR | 184 (38%) | 55 (12%) | |
SD | 159 (33%) | 219 (46%) | |
PD | 79 (17%) | 152 (32%) | |
ORR | 194 (40.6%) | 59 (12.4%) | P < 0.0001 |
DCR | 353 (73.8%) | 278 (58.4%) | P < 0.0001 |
- Citation: Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807
- URL: https://www.wjgnet.com/1007-9327/full/v25/i7/789.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i7.789